AbbVie Broadens Qulipta Migraine Indication As Anti-CGRP Competition Grows
Approval Comes Month After New Pfizer Product
Executive Summary
AbbVie’s migraine franchise expanded with US FDA approval of Qulipta for chronic migraine prevention, but its CGRP inhibitors are facing off against a pair of rivals acquired by Pfizer last year.
You may also be interested in...
AbbVie: Expect Smaller Deals Near-Term After 2023’s Big Finish
At the J.P. Morgan conference, AbbVie president Robert Michael said the company must effectively integrate ImmunoGen and Cerevel, which it expects to drive long-term growth.
Finance Watch: Impel’s Cash Has Nearly Run Out Despite Commercial Push
Restructuring Edition: Impel eliminated R&D spending earlier this year to focus on Trudhesa commercialization, but is examining all options, including bankruptcy, as its funding runs out. Also, Alaunos, BioXcel and others announce job cuts and strategic shifts during second quarter updates.
AbbVie Wary Of IRA Potential Impact On Struggling Imbruvica
While AbbVie tries to estimate which of its products might fall into CMS price negotiations, it is seeing lower-than-expected sales erosion for Humira and continued growth for Skyrizi and Rinvoq.